NCI-MATCH：一项针对多种肿瘤组织学类型的全国性协作精准肿瘤学试验。
The NCI-MATCH: A National, Collaborative Precision Oncology Trial for Diverse Tumor Histologies.
作者信息
Murciano-Goroff Yonina R, Drilon Alexander, Stadler Zsofia K
机构信息
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.
出版信息
Cancer Cell. 2021 Jan 11;39(1):22-24. doi: 10.1016/j.ccell.2020.12.021.
Abstract
The NCI-MATCH is a national master protocol trial, published in the Journal of Clinical Oncology, in which diverse tumors are sequenced and patients assigned to treatment. The trial demonstrates the feasibility of identifying rare and common actionable genetic alterations and underscores the strength of academic/community partnerships for improving trial access.
摘要
NCI-MATCH是一项发表于《临床肿瘤学杂志》的全国性主方案试验，其中对多种肿瘤进行测序，并为患者分配治疗方案。该试验证明了识别罕见和常见可操作基因改变的可行性，并强调了学术/社区伙伴关系在改善试验准入方面的优势。
相似文献
1
The NCI-MATCH: A National, Collaborative Precision Oncology Trial for Diverse Tumor Histologies.
Cancer Cell. 2021 Jan 11;39(1):22-24. doi: 10.1016/j.ccell.2020.12.021.
2
Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
Curr Probl Cancer. 2017 May-Jun;41(3):182-193. doi: 10.1016/j.currproblcancer.2017.02.001. Epub 2017 Feb 11.
3
Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.
Curr Probl Cancer. 2017 May-Jun;41(3):201-211. doi: 10.1016/j.currproblcancer.2017.05.003.
4
National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Am Soc Clin Oncol Educ Book. 2014:71-6. doi: 10.14694/EdBook_AM.2014.34.71.
5
National Cancer Institute Basket/Umbrella Clinical Trials: MATCH, LungMAP, and Beyond.
Cancer J. 2019 Jul/Aug;25(4):272-281. doi: 10.1097/PPO.0000000000000389.
6
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design.
J Natl Cancer Inst. 2020 Oct 1;112(10):1021-1029. doi: 10.1093/jnci/djz245.
7
An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
Chin Clin Oncol. 2015 Sep;4(3):31. doi: 10.3978/j.issn.2304-3865.2015.08.01.
8
Is the NCI MATCH trial a match for gynecologic oncology?
Gynecol Oncol. 2016 Jan;140(1):161-6. doi: 10.1016/j.ygyno.2015.11.003. Epub 2015 Nov 14.
9
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
J Clin Oncol. 2020 Nov 20;38(33):3883-3894. doi: 10.1200/JCO.19.03010. Epub 2020 Oct 13.
10
Implementation of "clinical sequencing" in cancer genome medicine in Japan.
Cancer Sci. 2018 Mar;109(3):507-512. doi: 10.1111/cas.13486. Epub 2018 Feb 2.
引用本文的文献
1
Molecular pathology of lymphoma and its treatment strategies: from mechanistic elucidation to precision medicine.
Front Immunol. 2025 Jul 9;16:1620895. doi: 10.3389/fimmu.2025.1620895. eCollection 2025.
2
The nationwide survey of Japanese public opinion about off-label use of anticancer drugs recommended by comprehensive genomic profiling.
Int J Clin Oncol. 2025 Jul 18. doi: 10.1007/s10147-025-02809-y.
3
Personalized High-Resolution Genetic Diagnostics of Prostate Adenocarcinoma Guided by Multiparametric Magnetic Resonance Imaging: Results of a Pilot Study.
Int J Mol Sci. 2025 Jun 12;26(12):5648. doi: 10.3390/ijms26125648.
4
First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors: 1-Year Follow-Up of the FIRST-Dx Study.
Cancer Sci. 2025 Jul;116(7):1908-1919. doi: 10.1111/cas.70077. Epub 2025 Apr 11.
5
Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial.
Nat Med. 2025 May;31(5):1502-1508. doi: 10.1038/s41591-025-03613-x. Epub 2025 Apr 7.
6
Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.
Cochrane Database Syst Rev. 2025 Mar 24;3(3):CD014872. doi: 10.1002/14651858.CD014872.pub2.
7
Tumor-Agnostic Therapies in Practice: Challenges, Innovations, and Future Perspectives.
Cancers (Basel). 2025 Feb 26;17(5):801. doi: 10.3390/cancers17050801.
8
Molecular and modular intricacies of precision oncology.
Front Immunol. 2024 Oct 23;15:1476494. doi: 10.3389/fimmu.2024.1476494. eCollection 2024.
9
Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer.
Nat Commun. 2024 Jul 11;15(1):5837. doi: 10.1038/s41467-024-49944-0.
10
Basket Trials: Past, Present, and Future.
Annu Rev Cancer Biol. 2024 Jun;8(1):59-80. doi: 10.1146/annurev-cancerbio-061421-012927. Epub 2023 Dec 5.
本文引用的文献
1
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.
JCO Precis Oncol. 2022 Jul;6:e2200165. doi: 10.1200/PO.22.00165.
2
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
Lancet Oncol. 2020 Dec;21(12):1589-1601. doi: 10.1016/S1470-2045(20)30475-7. Epub 2020 Oct 27.
3
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
Nat Med. 2020 Dec;26(12):1852-1858. doi: 10.1038/s41591-020-1089-8. Epub 2020 Oct 26.
4
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
J Clin Oncol. 2020 Nov 20;38(33):3883-3894. doi: 10.1200/JCO.19.03010. Epub 2020 Oct 13.
5
Dabrafenib and Trametinib in Patients With Tumors With Mutations: Results of the NCI-MATCH Trial Subprotocol H.
J Clin Oncol. 2020 Nov 20;38(33):3895-3904. doi: 10.1200/JCO.20.00762. Epub 2020 Aug 6.
6
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design.
J Natl Cancer Inst. 2020 Oct 1;112(10):1021-1029. doi: 10.1093/jnci/djz245.
7
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.
J Natl Cancer Inst. 2018 Oct 1;110(10):1067-1074. doi: 10.1093/jnci/djy024.
8
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.
9
FOCUS4: a new trial design for evaluation of targeted drugs in colorectal cancer?
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):143-145. doi: 10.1016/S2468-1253(17)30402-8. Epub 2017 Dec 16.
10
Improved overall survival in melanoma with combined dabrafenib and trametinib.
N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.
Zotero 插件